What question did this study set out to answer?

To evaluate the 12-month safety and efficacy of tafamidis in Chinese patients with symptomatic transthyretin amyloid cardiomyopathy.

May 23, 2025Cardiology and TherapyOpen Access

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Authors

ZTZhuang TianChinese Academy of Medical Sciences & Peking Union Medical College DPDaoquan PengCentral South University WMWei MaPeking University

Discussion

Member takes

Implication

Randomized trial demonstrates stable disease and tolerable safety with tafamidis in transthyretin amyloid cardiomyopathy, indicating sustained therapeutic stability.

Key Points

To evaluate the 12-month safety and efficacy of tafamidis in Chinese patients with symptomatic transthyretin amyloid cardiomyopathy.
Multicenter, open-label, single-arm interventional trial in China (NCT04814186) administering once-daily tafamidis free acid 61 mg for 12 months to 53 patients with symptomatic ATTR-CM.
Assessed ongoing safety and evaluated efficacy at months 6 and 12 using 6-minute walk test distance, NYHA classification, biomarker levels (NT-proBNP, troponin I), and health-related quality-of-life questionnaires.
Treatment-emergent adverse events (TEAEs) occurred in 85% of patients over a median exposure of 345 days, with no severe or serious treatment-related TEAEs reported.
Minimal changes from baseline were observed across all efficacy parameters at 6 and 12 months, with at least 44% of patients achieving clinically relevant stability or improvement on every endpoint.

Cite This Study

Tian et al. (2025) studied this question.

synapsesocial.com/papers/6aa9573265c13be784462e8d https://doi.org/10.1007/s40119-025-00408-6

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates stable disease and tolerable safety with tafamidis in transthyretin amyloid cardiomyopathy, indicating sustained therapeutic stability.

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider